No Data
Beijing Centergate Technologies (000931.SZ): ShanDong Huasu has received a utility model patent certificate.
Gelonghui reported on December 18 that Beijing Centergate Technologies (000931.SZ) announced that recently, ShanDong Huasu Pharmaceutical Co., Ltd., a subsidiary of Beijing Centergate Technologies Development (Holding) Co., Ltd., obtained a utility model patent certificate issued by the National Intellectual Property Office for a raw material tank cover that is convenient for installation and disassembly.
Beijing Centergate Technologies (000931.SZ): The application for marketing authorization of Peking Huaisu's acetaminophen and oxycodone tablets has been accepted.
On December 18, Glonghui reported that Beijing Centergate Technologies (000931.SZ) announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd. (hereinafter referred to as: Beijing Huasu), recently received the 'Acceptance Notification' issued by the National Medical Products Administration, indicating that the application for marketing authorization for oxycodone and acetaminophen tablets (specification: each tablet contains 5mg of hydrochloride oxycodone and 325mg of acetaminophen) has been accepted. Oxycodone and acetaminophen tablets are indicated for the treatment of moderate to severe pain that is severe enough to require the use of opioid analgesics and lacks alternative treatments.
Beijing Centergate Technologies (000931.SZ): The company's Pharmaceutical has been included in the 2024 National Medical Insurance Directory.
On December 11, Gelonghui announced that Beijing Centergate Technologies (000931.SZ) stated that its wholly-owned subsidiary SIHUAN PHARM holds Beijing Huasu, ShanDong Huasu, and SIHUAN PHARM controlled Duoduo Pharmaceutical have a total of 34 products included in the "Medical Insurance Catalogue 2024." This includes products such as bisoprolol fumarate tablets, benidipine hydrochloride tablets, oxycodone hydrochloride tablets, and naloxone hydrochloride injection, which were originally included in the 2023 National Medical Insurance Catalogue. The selected products remain unchanged compared to the "Medical Insurance Catalogue 2023." The future sales situation of the included products may be affected by multiple factors such as changes in the market environment and will not impact the current operation of the company.
Beijing Centergate Technologies (000931.SZ): Vice President Wang Bo resigned due to job changes.
On December 4th, Gelonghui reported that Beijing Centergate Technologies (000931.SZ) announced that the company's board of directors recently received a written resignation letter submitted by Mr. Wang Bo, the vice president of the company. Mr. Wang applied to resign from his position as vice president due to job changes, and after his resignation, he will no longer hold any position in the company. As of the date of this announcement, Mr. Wang does not hold any shares in the company and there are no commitments that he should have fulfilled but has not.
Beijing Centergate Technologies (000931.SZ): Subsidiary company Duoduo Pharmaceutical received the "Acceptance Notice" for Nifurtimox tablets from the National Medical Products Administration.
November 12th, Beijing Centergate Technologies (000931.SZ) announced that its subsidiary, Duoduo Pharmaceutical, recently received the "Acceptance Letter" issued by the National Medical Products Administration, accepting the registration application for Febuxostat tablets (specifications: 20mg, 40mg). Duoduo Pharmaceutical's Febuxostat tablets (specifications: 20mg, 40mg) were launched for research in 2022, and the indication for this application is for the long-term treatment of hyperuricemia in gout patients, not recommended for hyperuricemia without clinical symptoms.
Zhongguancun: Report for the third quarter of 2024
